1. Alcazar JL, Merce LT, Laparte C et al. (2003) A new scoring system to differentiate benign from malignant adnexal masses. Am J Obstetric Gynecol 237: 163–167
2. Bastert G (1996) Spezielle gynäkologische Onkologie II. In: Klinik der Frauenheilkunde und Geburtshilfe, Bd 12. Urban & Schwarzenberg: 1–110
3. Bertelsen K (1990) Tumor reduction surgery and long-term survival in advanced ovarian cancer: a DACOVA study. Gynecol Oncol 38(2): 203–209
4. Borgfeldt C, Andolf E (2004) Cancer risk after hospital discharge diagnosis of benign ovarian cysts and endometriosis. Acta Obstet Gynecol Scand 83: 395–400
5. Bowman A, Gabra H, Langdon SP, Lessells A, Stewart M, Young A, Smyth JF (2002 ) CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup. Clin Cancer Res 8(7): 2233–2239